Announcements
- Karolinska Developments årsstämma 2024
- Karolinska Development’s Annual General Meeting 2024
- Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC
- Delårsrapport för januari – mars 2024
- Interim Report - January-March 2024
- Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
- Notice of Annual General Meeting in Karolinska Development AB (publ)
- Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva säkerhetsdata från första delen av bolagets fas 1b/2-studie i PBC
More ▼
Key statistics
On Wednesday, Karolinska Development AB (2I9:STU) closed at 0.1156, 17.72% above the 52 week low of 0.0982 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1156 |
---|---|
High | 0.1156 |
Low | 0.1156 |
Bid | 0.1154 |
Offer | 0.1546 |
Previous close | 0.1222 |
Average volume | 0.00 |
---|---|
Shares outstanding | 267.52m |
Free float | 94.80m |
P/E (TTM) | 12.65 |
Market cap | 421.62m SEK |
EPS (TTM) | 0.1245 SEK |
Data delayed at least 15 minutes, as of May 22 2024.
More ▼